AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26427533 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived arm strength (SIS 1a)
Number of subjects: 99
Study 26427533 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived grip strength (SIS 1b)
Number of subjects: 99
Study 26427533 — intervention group
Group type: EXPERIMENTAL
Intervention: Dichotomized SIS (cut-off 80%)
Number of subjects: 99
Study 26427534 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased insulin resistance in men
Number of subjects: 112
Study 26427534 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased insulin resistance in women
Number of subjects: 112
Study 26427534 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration since diabetes diagnosis
Number of subjects: 112
Study 26427534 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI
Number of subjects: 112
Study 26427534 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA1c levels
Number of subjects: 112
Study 26427727 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide treatment
Number of subjects: 0
Study 26427727 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 0
Study 26428249 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapentadol ER (100-250 mg BID)
Number of subjects: 1154
Study 26428249 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapentadol ER
Number of subjects: 1154
Study 26428319 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea (HU) 1000 or 1500 mg/day (20 mg/kg/day, twice daily) and verapamil sustained-release tablets (120-240 mg/day)
Number of subjects: 7
Study 26428319 — intervention group
Group type: EXPERIMENTAL
Intervention: Xenograft studies with similar dosing of HU and verapamil
Number of subjects: 7
Study 26428486 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludarabine (30 mg/m(2)/day for 5 days on days -6 to -2) and melphalan (100 mg/m(2) on day -2)
Number of subjects: 26
Study 26428486 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludarabine and melphalan conditioning therapy
Number of subjects: 26
Study 26428486 — intervention group
Group type: EXPERIMENTAL
Intervention: Donor lymphocyte infusions
Number of subjects: 26
Study 26428846 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress hyperglycaemia during ICU stay
Number of subjects: 338
Study 26428846 — intervention group
Group type: EXPERIMENTAL
Intervention: FINDRISC score
Number of subjects: 338
Study 26428846 — intervention group
Group type: EXPERIMENTAL
Intervention: SAPS3 score
Number of subjects: 338
Study 26428846 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily caloric intake during ICU stay
Number of subjects: 338
Study 26428987 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-gauge needle
Number of subjects: 160
Study 26428987 — intervention group
Group type: COMPARATOR
Intervention: 15-gauge needle
Number of subjects: 160
Study 26429100 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 1214
Study 26429100 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 1214
Study 26429100 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-assisted tobacco intervention
Number of subjects: 1214
Study 26429135 — intervention group
Group type: EXPERIMENTAL
Intervention: Transpulmonary thermodilution using the VolumeView™ system
Number of subjects: 20
Study 26429135 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary artery continuous thermodilution
Number of subjects: 20
Study 26429135 — intervention group
Group type: EXPERIMENTAL
Intervention: Calibrated pulse contour analysis
Number of subjects: 20
Study 26429135 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncalibrated pulse contour analysis
Number of subjects: 20
Study 26429296 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab (AC-TH)
Number of subjects: 901
Study 26429296 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin and cyclophosphamide followed by paclitaxel (AC-T)
Number of subjects: 901
Study 26429339 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinician-supported inpatient self-managed insulin
Number of subjects: 336
Study 26429745 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnosis and treatment strategy for obstructive sleep apnea (OSA)
Number of subjects: 73
Study 26429963 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous magnesium
Number of subjects: 0
Study 26429963 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 0
Study 26430171 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Number of subjects: 85
Study 26430465 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin-D group (48 μg of vitamin-D + 800 mg calcium)
Number of subjects: 40
Study 26430465 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (800 mg calcium)
Number of subjects: 40
Study 26430892 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuminuria (measured by urinary albumin-to-creatinine ratio, ACR)
Number of subjects: 1456
Study 26430892 — intervention group
Group type: COMPARATOR
Intervention: ACR <30 mg/g (reference group)
Number of subjects: 1456
Study 26431695 — intervention group
Group type: EXPERIMENTAL
Intervention: howRu questionnaire
Number of subjects: 90
Study 26431695 — intervention group
Group type: EXPERIMENTAL
Intervention: howRwe questionnaire
Number of subjects: 90
Study 26432008 — intervention group
Group type: EXPERIMENTAL
Intervention: Brivaracetam (BRV) 200mg/day
Number of subjects: 29
Study 26432046 — intervention group
Group type: EXPERIMENTAL
Intervention: Ponatinib 45 mg daily for the first 14 days of cycle 1 then continuously for subsequent cycles, combined with hyper-CVAD chemotherapy (cyclophosphamide, vincristine, doxorubicin, dexamethasone, high-dose methotrexate, and cytarabine) every 21 days.
Number of subjects: 37
Study 26432046 — intervention group
Group type: EXPERIMENTAL
Intervention: Ponatinib maintenance 45 mg daily with vincristine and prednisone monthly for 2 years followed by ponatinib indefinitely.
Number of subjects: 37
Study 26432420 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotic treated SCZs
Number of subjects: 25
Study 26432420 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotic free SCZs
Number of subjects: 25
Study 26432420 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (HCs)
Number of subjects: 25
Study 26432420 — intervention group
Group type: EXPERIMENTAL
Intervention: SCZ smokers
Number of subjects: 25
Study 26432420 — intervention group
Group type: EXPERIMENTAL
Intervention: SCZ nonsmokers
Number of subjects: 25
Study 26432721 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid coronary revascularization (HCR)
Number of subjects: 100
Study 26433580 — intervention group
Group type: EXPERIMENTAL
Intervention: Eribulin mesylate 1.1 mg/m(2) (moderate impairment)
Number of subjects: 19
Study 26433580 — intervention group
Group type: EXPERIMENTAL
Intervention: Eribulin mesylate 0.7 mg/m(2) (severe impairment)
Number of subjects: 19
Study 26433580 — intervention group
Group type: EXPERIMENTAL
Intervention: Eribulin mesylate 1.4 mg/m(2) (normal renal function)
Number of subjects: 19
Study 26433580 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated dose reduction to eribulin 1.1 mg/m(2) (moderate/severe renal impairment)
Number of subjects: 19
Study 26433580 — intervention group
Group type: COMPARATOR
Intervention: All groups (normal, moderate, severe)
Number of subjects: 19
Study 26434510 — intervention group
Group type: EXPERIMENTAL
Intervention: CTO percutaneous coronary intervention techniques
Number of subjects: 0
Study 26435425 — intervention group
Group type: EXPERIMENTAL
Intervention: Parathyroid adenomectomy (PTX)
Number of subjects: 150
Study 26435832 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased structural covariance among subcortical regions and between subcortical and cortical regions
Number of subjects: 55
Study 26435832 — intervention group
Group type: EXPERIMENTAL
Intervention: Striatum and amygdala involvement
Number of subjects: 55
Study 26435832 — intervention group
Group type: EXPERIMENTAL
Intervention: Structural associations specific to IS
Number of subjects: 55
Study 26435889 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranial electrical stimulation (CES) applied via electrodes on the ear for 1 hour daily
Number of subjects: 167
Study 26435889 — intervention group
Group type: COMPARATOR
Intervention: Sham device
Number of subjects: 167
Study 26436130 — intervention group
Group type: EXPERIMENTAL
Intervention: Ponatinib 45 mg per day (initially), later reduced to 30 mg or 15 mg per day due to tolerability issues, with aspirin 81 mg daily.
Number of subjects: 51
Study 26436130 — intervention group
Group type: EXPERIMENTAL
Intervention: Ponatinib treatment (overall), with dose adjustments and monitoring.
Number of subjects: 51
Study 26436448 — intervention group
Group type: EXPERIMENTAL
Intervention: ABR regimen (alemtuzumab, belatacept, and rapamycin)
Number of subjects: 30
Study 26436448 — intervention group
Group type: COMPARATOR
Intervention: Conventional immunosuppression
Number of subjects: 30
Study 26437217 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin analogues (SSAs)
Number of subjects: 354
Study 26437664 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-to-vigorous physical activity (MVPA) as a covariate in ANCOVA models
Number of subjects: 1122
Study 26437664 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower levels of MVPA
Number of subjects: 1122
Study 26437664 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedentary behavior
Number of subjects: 1122
Study 26438146 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Navigation (PN)
Number of subjects: 2233
Study 26438146 — intervention group
Group type: COMPARATOR
Intervention: Usual care or usual care plus cancer educational materials (Control)
Number of subjects: 2233
Study 26438201 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid artery intima media thickness assessment
Number of subjects: 355
Study 26438201 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of atheromatous plaque
Number of subjects: 355
Study 26438201 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnosis of subclinical atherosclerosis
Number of subjects: 355
Study 26438201 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin use
Number of subjects: 355
Study 26438201 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation with UKPDS and Framingham risk scores
Number of subjects: 355
Study 26438201 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevalence of subclinical atherosclerosis in low risk group
Number of subjects: 355
Study 26438201 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced age
Number of subjects: 355
Study 26438201 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased waist circumference and longer diabetes duration
Number of subjects: 355
Study 26438349 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV counselling and testing services
Number of subjects: 40
Study 26438349 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical cancer screening and HIV care
Number of subjects: 40
Study 26438349 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-natal care and HIV care
Number of subjects: 40
Study 26438349 — intervention group
Group type: EXPERIMENTAL
Intervention: Family planning and sexually transmitted infection treatment
Number of subjects: 40
Study 26438349 — intervention group
Group type: EXPERIMENTAL
Intervention: Integration of HIV and SRH services
Number of subjects: 40
Study 26438497 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin plus rifampin
Number of subjects: 101
Study 26438497 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin plus rifampin
Number of subjects: 101
Study 26438497 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin plus clindamycin
Number of subjects: 101
Study 26438497 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin plus amoxicillin-clavulanate
Number of subjects: 101
Study 26438497 — intervention group
Group type: EXPERIMENTAL
Intervention: Empirical antibiotic combination therapy
Number of subjects: 101
Study 26438711 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferred consent for emergency admissions (n = 1178)
Number of subjects: 1358
Study 26438711 — intervention group
Group type: COMPARATOR
Intervention: Prospective consent for elective admissions (n = 641)
Number of subjects: 1358
Study 26438711 — intervention group
Group type: EXPERIMENTAL
Intervention: Consent obtained for emergency admissions (n = 1298)
Number of subjects: 1358
Study 26438711 — intervention group
Group type: COMPARATOR
Intervention: Non-consented patients (n = 314)
Number of subjects: 1358
Study 26439129 — intervention group
Group type: EXPERIMENTAL
Intervention: MVA Smallpox Vaccine (IMVAMUNE), 2 doses subcutaneously, 4 weeks apart
Number of subjects: 632
Study 26439129 — intervention group
Group type: EXPERIMENTAL
Intervention: MVA Smallpox Vaccine (IMVAMUNE)
Number of subjects: 632
Study 26439440 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal FADS2 genotype and DNA methylation
Number of subjects: 65
Study 26439440 — intervention group
Group type: EXPERIMENTAL
Intervention: Arachidonic acid intake
Number of subjects: 65
Study 26439440 — intervention group
Group type: EXPERIMENTAL
Intervention: Intake of 3 major n-3 species (eicosapentaenoic, docosapentaenoic, and docosahexaenoic acids)
Number of subjects: 65
Study 26439440 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal FADS2 methylation
Number of subjects: 65
Study 26439440 — intervention group
Group type: EXPERIMENTAL
Intervention: FADS2 genotype and DNA methylation in toddlers
Number of subjects: 65
Study 26440706 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose arsenic trioxide (0.005 mg/kg/day for 3 days) administered before chemotherapy cycles 2, 4, and 6
Number of subjects: 26
Study 26440706 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy cycles 1, 3, and 5 (baseline)
Number of subjects: 26
Study 26441156 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-generation antipsychotics
Number of subjects: 487
Study 26441156 — intervention group
Group type: COMPARATOR
Intervention: Control group (unexposed infants)
Number of subjects: 487
Study 26441155 — intervention group
Group type: EXPERIMENTAL
Intervention: Youths with DBD and low levels of callous-unemotional traits
Number of subjects: 56
Study 26441155 — intervention group
Group type: EXPERIMENTAL
Intervention: Youths with DBD
Number of subjects: 56
Study 26441155 — intervention group
Group type: EXPERIMENTAL
Intervention: Youths with DBD and low callous-unemotional traits
Number of subjects: 56
Study 26441155 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventromedial prefrontal cortex-amygdala connectivity
Number of subjects: 56
Study 26441155 — intervention group
Group type: EXPERIMENTAL
Intervention: Dysfunctional ventromedial prefrontal cortex-amygdala connectivity
Number of subjects: 56
Study 26441155 — intervention group
Group type: COMPARATOR
Intervention: Healthy youths
Number of subjects: 56
Study 26441187 — intervention group
Group type: EXPERIMENTAL
Intervention: Open Release Surgery
Number of subjects: 0
Study 26441187 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic Release Surgery
Number of subjects: 0
Study 26442234 — intervention group
Group type: EXPERIMENTAL
Intervention: Myofascial structural integration therapy (n=15)
Number of subjects: 29
Study 26442234 — intervention group
Group type: COMPARATOR
Intervention: Waitlist-Control (n=9)
Number of subjects: 29
Study 26442234 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent surveys
Number of subjects: 29
Study 26443344 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal ultrasound (US) by senior physicians
Number of subjects: 22
Study 26443344 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 scan-fast exam (epigastrium and right hypochondrium)
Number of subjects: 22
Study 26443344 — intervention group
Group type: COMPARATOR
Intervention: Abdominal radiography
Number of subjects: 22
Study 26443344 — intervention group
Group type: COMPARATOR
Intervention: Junior reviewers evaluating US
Number of subjects: 22
Study 26444282 — intervention group
Group type: EXPERIMENTAL
Intervention: Anakinra (ANA) 100 mg daily for one year
Number of subjects: 17
Study 26444282 — intervention group
Group type: COMPARATOR
Intervention: Historical cohort of 47 patients
Number of subjects: 17
Study 26444662 — intervention group
Group type: EXPERIMENTAL
Intervention: FFRCT
Number of subjects: 51
Study 26444662 — intervention group
Group type: EXPERIMENTAL
Intervention: TAG320
Number of subjects: 51
Study 26444662 — intervention group
Group type: COMPARATOR
Intervention: CT coronary angiography alone
Number of subjects: 51
Study 26445139 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled loxapine (10 mg)
Number of subjects: 60
Study 26445139 — intervention group
Group type: COMPARATOR
Intervention: Inhaled placebo
Number of subjects: 60
Study 26445139 — intervention group
Group type: COMPARATOR
Intervention: Oral moxifloxacin (400 mg; positive control)
Number of subjects: 60
Study 26445642 — intervention group
Group type: EXPERIMENTAL
Intervention: Benchmarking group
Number of subjects: 797
Study 26445642 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 797
Study 26445691 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacogenetic testing
Number of subjects: 685
Study 26445924 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin treatment for 18 months
Number of subjects: 85
Study 26446126 — intervention group
Group type: EXPERIMENTAL
Intervention: NREM sleep desaturation (NREMDes) patients (n = 59)
Number of subjects: 115
Study 26446483 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma α-tocopherol concentrations
Number of subjects: 500
Study 26446483 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma γ-tocopherol concentrations
Number of subjects: 500
Study 26446491 — intervention group
Group type: EXPERIMENTAL
Intervention: DJBL treatment
Number of subjects: 17
Study 26446943 — intervention group
Group type: EXPERIMENTAL
Intervention: BRAF mutation-positive cfDNA
Number of subjects: 732
Study 26446943 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabrafenib and Trametinib
Number of subjects: 732
Study 26447149 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral Nutrition
Number of subjects: 2912
Study 26447149 — intervention group
Group type: COMPARATOR
Intervention: Enteral Nutrition
Number of subjects: 2912
Study 26447158 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum retinol (SR) concentration adjusted for inflammation in Zambian children
Number of subjects: 165
Study 26447158 — intervention group
Group type: EXPERIMENTAL
Intervention: Marker-adjusted SR cutoffs of 0.6 μmol/L for late convalescence and 0.5 μmol/L for early convalescence
Number of subjects: 165
Study 26447158 — intervention group
Group type: COMPARATOR
Intervention: Total liver reserves (TLRs)
Number of subjects: 165
Study 26447158 — intervention group
Group type: COMPARATOR
Intervention: Serum retinol (SR) concentrations
Number of subjects: 165
Study 26447761 — intervention group
Group type: EXPERIMENTAL
Intervention: od-value thresholds for infarct size > 100 ml
Number of subjects: 108
Study 26447761 — intervention group
Group type: EXPERIMENTAL
Intervention: od-value thresholds for infarct size > 70 ml
Number of subjects: 108
Study 26447761 — intervention group
Group type: EXPERIMENTAL
Intervention: od-value compared to volumetric measures
Number of subjects: 108
Study 26447761 — intervention group
Group type: EXPERIMENTAL
Intervention: od-value compared to visual estimations and ABC/2 method
Number of subjects: 108
Study 26448169 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of substance P-derived peptide FGLM-amide and IGF-1-derived peptide SSSR
Number of subjects: 0
Study 26448169 — intervention group
Group type: EXPERIMENTAL
Intervention: Substance P and insulin-like growth factor 1 (IGF-1)
Number of subjects: 0
Study 26448724 — intervention group
Group type: EXPERIMENTAL
Intervention: Variable dose warfarin (first dose on the night preceding surgery with subsequent target INR 2.0-2.5)
Number of subjects: 355
Study 26448724 — intervention group
Group type: EXPERIMENTAL
Intervention: Fondaparinux 2.5 mg daily starting 6-18 h postoperatively
Number of subjects: 355
Study 26448724 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed 1.0 mg dose warfarin daily starting 7 days preoperatively
Number of subjects: 355
Study 26448724 — intervention group
Group type: COMPARATOR
Intervention: Fixed low dose warfarin
Number of subjects: 355
Study 26448868 — intervention group
Group type: EXPERIMENTAL
Intervention: Skeletal muscle citrate synthase (CS) activity
Number of subjects: 25
Study 26448868 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal complex 2 driven mitochondrial respiration
Number of subjects: 25
Study 26448868 — intervention group
Group type: EXPERIMENTAL
Intervention: HOMA-IR
Number of subjects: 25
Study 26448868 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin
Number of subjects: 25
Study 26448901 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral QLT091001 administered once daily for 7 days
Number of subjects: 32
Study 26449224 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy of temozolomide (TMZ) 150 mg/m² PO daily on days 1-5 and veliparib (ABT-888) 40 mg PO daily on days 1-7 of a 28-day cycle
Number of subjects: 16
Study 26449224 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy of temozolomide (TMZ) and veliparib (ABT-888)
Number of subjects: 16
Study 26449355 — intervention group
Group type: EXPERIMENTAL
Intervention: No mild cognitive impairment (MCI)
Number of subjects: 319
Study 26449355 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild cognitive impairment (MCI)
Number of subjects: 319
Study 26449355 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 319
Study 26449490 — intervention group
Group type: EXPERIMENTAL
Intervention: Exacerbation history in the year before baseline
Number of subjects: 2164
Study 26449490 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical regression equations
Number of subjects: 2164
Study 26449993 — intervention group
Group type: EXPERIMENTAL
Intervention: STRATIFY decision tool
Number of subjects: 1033
Study 26450421 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-dose BCG SSI
Number of subjects: 4
Study 26450421 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-dose BCG TICE
Number of subjects: 4
Study 26450421 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose BCG SSI
Number of subjects: 4
Study 26450421 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose BCG TICE
Number of subjects: 4
Study 26450424 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia in controlled diabetes mellitus (HbA1c < 7 %)
Number of subjects: 66